期刊文献+

拓扑替康与足叶乙甙及环磷酰胺联合治疗慢性粒细胞白血病急变的临床研究 被引量:1

下载PDF
导出
摘要 目的探讨拓扑替康与足叶乙甙及环磷酰胺组成TEC方案治疗慢性粒细胞白血病(CML)急变期的疗效及毒副作用。方法将34例患者确诊后即应用柔红霉素联合阿糖胞苷(DA)方案治疗,DA方案治疗两疗程后未达缓解或缓解后复发者均予TEC方案治疗两个疗程,其疗效及毒副作用均与DA方案作自身对照。所有患者定期检查血常规、骨髓及肝、肾功能等。分别观察两种方案的疗效及毒副作用。结果34例中经TEC方案治疗有14例达完全缓解,4例达部分缓解,完全缓解率为41.17%,总有效率为52.94%;16例无反应。主要毒副作用为骨髓抑制。TEC方案疗效优于DA方案,毒副作用无明显加重。结论TEC方案对CML急变期具有确切疗效,宜于临床推广。
出处 《临床血液学杂志》 CAS 2005年第6期365-366,共2页 Journal of Clinical Hematology
  • 相关文献

参考文献7

二级参考文献20

  • 1Kantarjian H. New developments in the treatment of acute myeloid leukemia: focus on topotecan. Semin Hematol, 1999,36(Suppl 8) :16-25.
  • 2Estey E H. Therapeutic options for acute myelogenous leukemia. Leuk Lymphoma, 2000,36 :479- 484.
  • 3Ulukan H, Swaan P W. Camptothecins: a review of their chemotherapeutic potential. Drugs, 2002,62:2039-2057.
  • 4Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 2000,9512637-2644.
  • 5Kantarjian H M, Beran M, Ellis A, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.Blood, 1993,81 : 1146- 1151.
  • 6Beran M, Kantarjian H, O'Brien S, et al Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 1996,88:2473- 2479.
  • 7Cortes J, Estey E, Beran M, et al. Cyelophosphamide,ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma, 2000,36:479-484.
  • 8Estey E H, Thall P F, Cortes J E, et al. Comparison of idarubiein + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 2001,98:3575- 3583.
  • 9Lee S T, Jang J H, Suh H C, et al. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol , 2001,68:237-4511.
  • 10Kantarjian HM,Giles FJ,O Brien SM,et al.Clinical course and therapy of chronic myelogenous leukemia with interferon alpha and chemotherapy [J].Hematol Oncol Clin North Am,1998,12:31- 80.

共引文献14

同被引文献8

  • 1KLUMPER E, PIETER R, VEERMAN A J, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia [J]. Blood, 1995,86:3861 --3868.
  • 2ULUKAN H, SWAAN P W. Camptotheeins: a review of their chemotherapeutic potential[J]. Drugs, 2000, 62:2039--2057.
  • 3WEIHRAUCH M R, STAIB P, SEIBERLICH B, et al. Phase I / II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia[J]. Leuk Lymphoma, 2004,45 : 699 -- 704.
  • 4CORTS J, ESTEY E, BERAN M, et al. Cyclophospha-mide,Ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia[J]. Leuk Lymphoma,2000,36:479--484.
  • 5KOLLMANNSBERGER C, MROSS K, JAKOB A, et al. Topotecan-A novel topoisomerase l inhibitor. Phamacology and clinical experience[J]. Oncology, 1999, 56:1-12.
  • 6AZIM H A J R, GANTI A K. Treatment options for relapsed small-cell lung cancer[J]. Anticancer Drugs, 2007,18:255--261.
  • 7陈协群,万幼峰,白庆咸,曹云新.拓扑异构酶Ⅰ抑制剂对K562细胞的杀伤与诱导凋亡作用[J].癌症,2002,21(4):356-359. 被引量:13
  • 8秦铁军.拓扑替康治疗恶性血液病研究现况[J].国外医学(输血及血液学分册),2002,25(3):240-243. 被引量:6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部